In 2012, the "European Autism Interventions - A Multicentre Study for Developing New Medications" (EU-AIMS) was launched as a collaboration for research for the treatment of autism. The aim of this collaboration is to contribute to a better understanding of autism and to develop new therapeutical approaches to improve the health status and quality of life of people with autism.
AIMS-2 Trials is coordinated by the Institute of Psychiatry, Psychology and Neuroscience (IoPPN) at King's College London. As part of this collaboration, the Scheiffele research group at the Biozentrum is involved in the development of animal models of autism and the identification of neuronal network anomalies that underlie autism spectrum disorders. The renewed funding of the "Innovative Medicines Initiative", with 115 million euros, enables the EU partnership to be continued in the future.